Alumis secures $259m to develop therapies for immune dysfunction

07 Mar 2024
www.pharmaceutical-technology.com
Phase 2Immunotherapy
Alumis secures $259m to develop therapies for immune dysfunction
Preview
Source: Pharmaceutical Technology
The funding will enable the development of Alumis’ data analytics and multi-platform approach to investigate ESK-001 for other autoimmune diseases. Credit: Mongkolchon Akesin / Shutterstock.com.
Alumis has secured $259m in a Series C funding round to progress the development of its clinical-stage pipeline of oral therapies to address immune dysfunction.
Life sciences investment company Foresite Capital and new investors Samsara BioCapital and venBio Partners jointly led the funding round.
Additional participation came from other new investors, including SR One, Cormorant Asset Management, Lilly Asia Ventures, Nextech and the Ally Bridge Group.
Alumis will use the funding proceeds to commence Phase III studies of its lead candidate, ESK-001, for moderate to severe plaque psoriasis, in the second half of this year.
The investment will also support two ongoing Phase II trials for the allosteric tyrosine kinase 2 inhibitor ESK-001 in systemic lupus erythematosus (SLE) and non-infectious uveitis.
See Also:
AD/PD 2024: exploring cutting-edge therapies for ALS
Alumis secures $259m to develop therapies for immune dysfunction
Preview
Source: Pharmaceutical Technology
BeiGene secures accelerated FDA approval for follicular lymphoma treatment
Alumis secures $259m to develop therapies for immune dysfunction
Preview
Source: Pharmaceutical Technology
The trials include the Phase II STRIDE trial and an open-label extension study in moderate to severe plaque psoriasis patients, as well as the Phase IIb LUMUS trial of ESK-001 for SLE patients, and the proof-of-concept Phase II OPTYK-1 trial in non-infectious uveitis.
The funding will enable the development of Alumis’ precision data analytics and multi-platform approach to investigate ESK-001’s potential in other autoimmune indications.
This includes A-005, a TYK2 inhibitorTYK2 inhibitor for treating neuroinflammatory and neurodegenerative ailments, and earlier-stage internal pipeline programmes.
Samsara BioCapital founder and managing general partner Srinivas Akkaraju and venBio Partners managing partner Richard Gaster will join the board of directors of Alumis.
Alumis president and CEO Martin Babler stated: “We are pleased to announce our successful Series C financing and we are grateful for the support of our strong investor syndicate, a group that shares our commitment to transforming the treatment paradigm for patients living with immune-mediated diseases.
“This investment will support the continued clinical development of ESK-001, building on promising data that have demonstrated full, sustained target inhibition leading to a potentially best-in-class oral TYK2 inhibitorTYK2 inhibitor profile. It will also support the continued advancement of additional pipeline programmes powered by our proprietary precision immunology platform for target discovery and clinical development.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.